NASDAQ:OPTN - OptiNose Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 308.92 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.09 (-3.24%)

This chart shows the closing price for OPTN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OptiNose Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPTN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPTN

Analyst Price Target is $11.00
▲ +308.92% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for OptiNose in the last 3 months. The average price target is $11.00, with a high forecast of $12.00 and a low forecast of $10.00. The average price target represents a 308.92% upside from the last price of $2.69.

This chart shows the closing price for OPTN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in OptiNose. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021Royal Bank of CanadaLower Price Target$17.00 ➝ $10.00Medium
5/6/2021Cantor FitzgeraldLower Price TargetOverweight$18.00 ➝ $12.00High
7/16/2020Piper SandlerReiterated RatingOverweight ➝ Market Perform$19.00Medium
7/16/2020Royal Bank of CanadaReiterated RatingOutperform$17.00Medium
3/25/2020Royal Bank of CanadaReiterated RatingBuy$17.00Low
3/5/2020Cantor FitzgeraldLower Price TargetOverweight$27.00 ➝ $21.00High
2/7/2020Piper SandlerReiterated RatingBuy$24.00Low
12/18/2019CowenInitiated CoverageOutperform$25.00Low
8/13/2019BMO Capital MarketsLower Price TargetOutperform$26.00 ➝ $24.00High
8/12/2019Royal Bank of CanadaSet Price TargetBuy$20.00Low
5/9/2019Cantor FitzgeraldReiterated RatingBuy$27.00High
4/23/2019Piper Jaffray CompaniesSet Price TargetBuy$29.00Low
3/7/2019Royal Bank of CanadaLower Price TargetOutperform$25.00High
2/4/2019Cantor FitzgeraldReiterated RatingBuy$27.00High
11/26/2018Cantor FitzgeraldReiterated RatingOverweightLow
11/14/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$30.00 ➝ $27.00High
8/15/2018Cantor FitzgeraldReiterated RatingOverweightLow
8/15/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$30.00 ➝ $28.00Medium
8/14/2018Piper Jaffray CompaniesSet Price TargetBuy$30.00High
8/14/2018Cantor FitzgeraldSet Price TargetBuy$30.00High
8/7/2018Cantor FitzgeraldInitiated CoverageOverweight$30.00High
7/18/2018Piper Jaffray CompaniesReiterated RatingBuy$34.00Medium
1/15/2018Piper Jaffray CompaniesSet Price TargetBuy$28.00Medium
11/7/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$33.00N/A
11/7/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$27.00N/A
11/7/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$27.00N/A
11/7/2017BMO Capital MarketsInitiated CoverageOutperform$29.00N/A
(Data available from 8/5/2016 forward)
OptiNose logo
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Read More

Today's Range

Now: $2.69
Low: $2.67
High: $2.85

50 Day Range

MA: $3.15
Low: $2.60
High: $3.76

52 Week Range

Now: $2.69
Low: $2.51
High: $7.04


131,343 shs

Average Volume

405,293 shs

Market Capitalization

$142.87 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of OptiNose?

The following sell-side analysts have issued reports on OptiNose in the last twelve months: Cantor Fitzgerald, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for OPTN.

What is the current price target for OptiNose?

2 Wall Street analysts have set twelve-month price targets for OptiNose in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 308.9%. Cantor Fitzgerald has the highest price target set, predicting OPTN will reach $12.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $10.00 for OptiNose in the next year.
View the latest price targets for OPTN.

What is the current consensus analyst rating for OptiNose?

OptiNose currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPTN will outperform the market and that investors should add to their positions of OptiNose.
View the latest ratings for OPTN.

What other companies compete with OptiNose?

How do I contact OptiNose's investor relations team?

OptiNose's physical mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company's listed phone number is 267-364-3500 and its investor relations email address is [email protected] The official website for OptiNose is